Juvenile arthritis damage index predicts poor response to biological treatment: A prospective cohort study

Table 5 Comparative analysis of clinical parameters of patients whose JADI-A improved vs remained unchanged/deteriorated on biologic disease-modified antirheumatic drugs therapy (end of study), n (%)

Parameter	Improved JADI-A, n = 38	Non-improved JADI-A, n = 14	P value
Baseline JADI-A, IQR	2 (1-6)	1.5 (1-2)	0.096
Patients with uveitis	2 (5.3)	2 (14.3)	0.278
Treatment with nbDMARDs at the EOS	38 (100)	9 (64.3)	0.001
Stable nbDMARD treatment during the study	37 (97.4)	8 (57.1)	0.001
Stable bDMARD treatment during the study	33 (86.8)	9 (64.3)	0.067
Bone osteonecrosis (JADI-E)	2 (5.3)	3 (21.4)	0.079
MRI-confirmed bone erosions	13/35 (37.1)	8/12 (66.7)	0.075
bDMARD treatment			0.249
Etanercept	17 (44.7)	5 (35.7)
Golimumab	2 (5.3)	3 (21.4)
Adalimumab	13 (34.2)	6 (42.8)
Tofacitinib	4 (10.5)	0 (0)
Secukinumab	2 (5.3)	0 (0)

JADI-A: Juvenile arthritis damage index - articular damage; nbDMARDs: Non-biologic disease-modified antirheumatic drugs; EOS: End of study; bDMARD: Biologic disease-modified antirheumatic drugs; JADI-E: Juvenile arthritis damage index - extraarticular damage; MRI: Magnetic resonance imaging; IQR: Interquartile range.